HSBC TUR.WAR.OP.END. NOVA/ DE000HS3ZTE3 /
2024-10-16 9:36:31 PM | Chg.+0.0200 | Bid9:59:14 PM | Ask9:59:14 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.2900EUR | +1.57% | 1.2900 Bid Size: 20,000 |
1.3100 Ask Size: 20,000 |
Novo Nordisk | 104.5389 USD | 2078-12-31 | Call |
Newsfile Corp
08-28
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
08-28
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising A...
GlobeNewswire
08-28
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
GlobeNewswire
08-27
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire
08-26
Dewpoint Therapeutics Awarded Target ALS Grant for the Second Time for Development of c-mods for Amy...
GlobeNewswire
08-21
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
GlobeNewswire
08-14
19th Annual Cardiometabolic Health Congress: Honoring the Life and Legacy of CMHC Co-Chair Dr. Georg...
GlobeNewswire
08-06
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire
08-01
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Dire...
GlobeNewswire
07-11
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansio...
GlobeNewswire
07-11
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pi...
GlobeNewswire
07-11
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pi...